Safety Issues of Biosimilar Products

Journal Title: Advances in Clinical Toxicology - Year 2019, Vol 4, Issue 3

Abstract

Biosimilars are not expected to be direct copies of biologic medicines and are therefore not the same as generic drugs. Due to the complex structure of biologic medicines and the processes involved in production, biosimilars must be shown on the basis of analytical, non-clinical and clinical data to be similar to an original biologic in terms of structural characteristics, and safety and efficacy. Minor differences with the active ingredient are expected and permitted so long as any such differences are demonstrated not to be clinically meaningful. In 2012, 7% of worldwide sales (US $53 billion) were at risk as a result of the free entry of generic drugs, which compete directly with the original brands, forcing them to lower their prices or, even worse, to stop producing them. By 2020, it is expected that this loss of profitability will reach US $259 billion. This is clear that biosimilars impose some goods in terms of availability and affordability but surely a discourage to invention of newer biotech products in future.

Authors and Affiliations

Mohiuddin AK*

Keywords

Related Articles

Addiction and Evolutionary Process, Common Aspects in Physio-Pathologic Pathways Useful in Pharmaco-Toxicological Approach

Observing vertebrates evolutionary in mammalian are present characteristic pathways involved in progeny take care in first period after birth. In this behavior and instinct, learning neuronal circuits are evolved and re...

Dietary Milk Consumption and the Pesticide Residues Exposure from Pasteurized and UHT samples

The multi residue analysis with QuEChERS sample preparation method was employed to evaluate cow milk samples containing up to 3% of fat. After the cleanup step with C18, the pesticides were analyzed by Agilent 7890A GC...

Waste Management of Seafood Processing Effluents, Hadhramout Governorate, Yemen

Wastewater samples were collected from the Hadhramout Governorate/Yemen. Ten wastewater samples were collected from the biggest three fish canning factories in Hadhramout Governorate/Yemen (Tuna for Canning Packing Fishi...

Advanced Cognitive Emotional Regulation Therapy (ACERT) for Addiction Treatment

The last decades have shown relevant improvement in the therapeutic strategies aimed at psychiatric symptoms; however, addiction treatment remains unclear and controversial. Although there are specific medications ap...

Neurotoxicity, Immunotoxicity and Drug Toxicity – A Review

Neurotoxicity is defined as a form of toxicity in which a biological, chemical and physical agent produces an adverse effect on the structure or function of the central and peripheral nervous system. It occurs mainly...

Download PDF file
  • EP ID EP751661
  • DOI 10.23880/act-16000158
  • Views 17
  • Downloads 0

How To Cite

Mohiuddin AK* (2019). Safety Issues of Biosimilar Products. Advances in Clinical Toxicology, 4(3), -. https://europub.co.uk/articles/-A-751661